Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 1998

View Archived Issues

Avax patents antifungal agents with novel mechanism of action

Statins provide health benefits in women with normal cholesterol

Novel aldose reductase inhibitor SG-210 for diabetic complications

Direct myocardial effects of OPC-18790

Zinc lozenges prove ineffective in treating common cold symptoms in children

Orlistat proves effective and well tolerated in the treatment of obesity

Additional phase III results reported for Cypress Bioscience's Prosorba Column

Phase I trial results for AG-2034 presented at NCI-EORTC symposium

Modulators of the activity of IL-13 investigated at Amrad

Human Genome Sciences presents novel chemokine, its preparation and use

New antitumor agent disclosed in patent literature by Taisho

Asta Medica investigates compounds for immune and allergic disorders

Glutamate transport blockers discovered using novel system developed at Suntory

Kyowa Hakko prepares new compounds for pruritus, asthma

Na+/H+ exchange inhibitors from Kanebo useful for cardiac ischemia

TZT-1027: mechanism of action and phase I results

Shionogi redirects development of TxA2 antagonist

Different schedules, doses of DX-8951f assessed in phase I

Spotlight on 5-HT1B/1D agonists for migraine

Favorable preliminary results for IntraDose in metastatic breast cancer and malignant melanoma

FDA, Janssen advise of Propulsid warning label changes

Scientifically tested hair loss treatment introduced in Canada

Teva to acquire Pharmachemie

Angiotech initiates phase I study of paclitaxel for the treatment of multiple sclerosis

Significant anti-HIV activity seen with Ziagen plus protease inhibitors

Agouron continues to expand anti-HIV pipeline

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...